Small molecule CRO/CDMO with AI-driven drug discovery and process optimization
PharmaResources operates a vertically integrated CRO/CDMO business spanning compound design, process chemistry, and API manufacturing. The tech stack reveals dual engineering tracks: a computational chemistry layer (Python, PyMOL, RDKit, TensorFlow, PyTorch, Deepseek, Qwen, Llama) driving an active AI molecule generation project, paired with analytical chemistry instrumentation (HPLC, LC-MS) for method development and purification. The research-heavy hiring mix (29 of 47 active roles) and leadership roles focused on process R&D and synthesis teams signal scaling of internal capability rather than outsourced development.
Notable leadership hires: Process R&D Director, Process R&D Lead, Synthesis Team Lead, Catalyst Lead
Founded in 2007, PharmaResources provides small molecule drug development and manufacturing services to global pharmaceutical companies. The business spans three verticals: drug discovery (compound screening and optimization), process research (synthesis innovation and scale-up), and API/intermediate production. The company operates from Shanghai with 1,001–5,000 employees, all hiring activity concentrated in China. Current projects span fluid chemistry optimization, nucleic acid purification methods, and factory-scale process transfers, while simultaneously advancing an AI molecule generation platform. Pain points center on technology transfer and commercialization, cost control in R&D and production, and meeting timelines as the CRO/CDMO business expands.
PharmaResources uses HPLC, LC-MS, Python, GCP, PyMOL, RDKit, TensorFlow, PyTorch, and LangChain. They also employ LLMs (Deepseek, Qwen, Llama) and RAG for drug discovery workflows, plus standard web frameworks (Flask, Django) and data tools (NumPy, Pandas, scikit-learn).
Yes. PharmaResources has 6 active engineering roles (out of 47 total) with a mix of junior, mid, and senior levels. Hiring velocity is decelerating. All positions are based in China.
Active projects include AI molecule generation, fluid chemistry process optimization, HPLC/LC-MS method development for nucleic acid purification, pharmacokinetic studies, and factory-scale process transfers. The company is also establishing information security policies.
Other companies in the same industry, closest in size